Regentis Biomaterials (RGNT) director details indirect share and warrant holdings

Rhea-AI Filing Summary

REGENTIS BIOMATERIALS LTD. director Jeff Dykan filed an initial ownership report showing indirect positions held through venture funds he manages. The filing lists 270,473 ordinary shares held by SCP Vitalife Partners II L.P. and 130,465 ordinary shares held by SCP Vitalife Partners (Israel) II L.P. Dykan is the general partner of these SCVP entities and holds voting and dispositive power over their shares. In addition, the SCVP funds hold warrants that are currently exercisable for 6,122 and 2,083 ordinary shares at an exercise price of $5.00 per share, each with a three-year term expiring on December 5, 2028.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dykan Jeff

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYEHUDIM

(Street)

HERZLIYA 4676652

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, no par value per share	270,473	I	See footnotes(1)(2)
Ordinary Shares, no par value per share	130,465	I	See footnotes(1)(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to purchase ordinary shares	12/05/2025	12/05/2028	Common Stock	6,122	$5	I	See footnotes(3)
Warrants to purchase ordinary shares	12/05/2025	12/05/2028	Common Stock	2,083	$5	I	See footnotes(4)

Explanation of Responses:

1. Consists of Consists of (1) 270,473 ordinary shares held by SCP Vitalife Partners II L.P. ("SCPVP II"); (2) 130,465 ordinary shares held by SCP Vitalife Partners (Israel) II L.P. ("SCVP II Israel", and, with SCVP II, the "SCVP Entities").

2. Reporting Person is the general partner of the SCVP Entities, and, as such, holds share voting and dispositive power over the shares held by SCVP Entities. The principal business address of SCP Vitalife Partners II L.P., is Messrs. Churchill and Weisman, 5 Great Valley Parkway, Suite 210, Malvern, Pennsylvania 19355. The principal business address of SCP Vitalife Partners (Israel) II L.P. is 15 Hatidhar, P.O. Box 2138, Raanana, Tel Aviv 4366517, Israel.

3. The warrants are currently exercisable and have a 3 year term, held by SCP Vitalife Partners II L.P

4. The warrants are currently exercisable and have a 3 year term, held by SCP Vitalife Partners (Israel) II L.P.

	/s/ Jeff Dykan	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Jeff Dykan’s Form 3 for REGENTIS BIOMATERIALS (RGNT) show?

The Form 3 shows Jeff Dykan’s indirect ownership in Regentis Biomaterials through SCP Vitalife funds. It lists substantial ordinary share holdings and currently exercisable warrants, establishing his baseline beneficial ownership as a director associated with these investment entities.

How many REGENTIS BIOMATERIALS ordinary shares are indirectly owned in this Form 3?

The filing reports 270,473 ordinary shares held by SCP Vitalife Partners II L.P. and 130,465 ordinary shares held by SCP Vitalife Partners (Israel) II L.P., all attributed to Jeff Dykan as general partner with voting and dispositive power over these SCVP entities.

What warrant positions related to REGENTIS BIOMATERIALS (RGNT) are disclosed for Jeff Dykan?

The Form 3 lists warrants currently exercisable for 6,122 and 2,083 ordinary shares of Regentis Biomaterials. Both series have a three-year term, a $5.00 per share exercise price, and expire on December 5, 2028, held by SCP Vitalife funds.

How does Jeff Dykan hold voting power over REGENTIS BIOMATERIALS shares in this filing?

According to the footnotes, Jeff Dykan is the general partner of the SCP Vitalife entities. In that role, he holds voting and dispositive power over the ordinary shares and warrants those funds own, giving him beneficial ownership influence without direct personal share registration.

Are the REGENTIS BIOMATERIALS warrants held by Jeff Dykan’s affiliated funds exercisable now?

Yes. The filing states the warrants are currently exercisable, have a three-year term, and are held by SCP Vitalife Partners II L.P. and SCP Vitalife Partners (Israel) II L.P. They carry a $5.00 exercise price and expire on December 5, 2028.

Does this REGENTIS BIOMATERIALS (RGNT) Form 3 show any insider buying or selling activity?

No specific buying or selling transactions are reported. The Form 3 functions as an initial statement of beneficial ownership, listing existing indirect holdings in ordinary shares and warrants rather than recording new market purchases or sales by Jeff Dykan or his affiliated funds.